4.7 Article

Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions

期刊

NEUROLOGY
卷 80, 期 17, 页码 1557-1564

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31828f17de

关键词

-

资金

  1. University of Arizona TRIF Imaging fellowship
  2. National Institute of Mental Health [RO1 MH57899]
  3. National Institute on Aging [9R01AG031581-10, P30 AG19610, R01AG025526]
  4. State of Arizona
  5. Advanced Research Institute for Biomedical Imaging
  6. Evelyn F. McKnight Brain Institute
  7. Banner Alzheimer's Foundation
  8. Mayo Clinic Foundation
  9. NIH (NIA)
  10. Mind and Life Institute
  11. Arizona Advanced Research Institute for Biomedical Imaging
  12. NIH
  13. Avid
  14. NIH/NIA
  15. Arizona Alzheimer's Research Consortium
  16. Anonymous Foundation
  17. Nomis Foundation
  18. AstraZeneca
  19. Avid/Eli Lilly

向作者/读者索取更多资源

Objective: To investigate whether higher fasting serum glucose levels in cognitively normal, nondiabetic adults were associated with lower regional cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer disease (AD). Methods: This is a cross-sectional study of 124 cognitively normal persons aged 64 +/- 6 years with a first-degree family history of AD, including 61 APOE epsilon 4 noncarriers and 63 carriers. An automated brain mapping algorithm characterized and compared correlations between higher fasting serum glucose levels and lower [F-18]-fluorodeoxyglucose-PET rCMRgl measurements. Results: As predicted, higher fasting serum glucose levels were significantly correlated with lower rCMRgl and were confined to the vicinity of brain regions preferentially affected by AD. A similar pattern of regional correlations occurred in the APOE epsilon 4 noncarriers and carriers. Conclusions: Higher fasting serum glucose levels in cognitively normal, nondiabetic adults may be associated with AD pathophysiology. Findings suggest that the risk imparted by higher serum glucose levels may be independent of APOE epsilon 4 status. This study raises additional questions about the role of the metabolic process in the predisposition to AD and supports the possibility of targeting these processes in presymptomatic AD trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据